Advances in the treatment of relapsed or refractory Hodgkin's lymphoma

Oncologist

Volumn 17, Issue 3, 2012, Pages 367-376

  Ramchandren, Radhakrishnan ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BENDAMUSTINE; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENTINOSTAT; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; MESNA; METHYLPREDNISOLONE; MITOXANTRONE; MOCETINOSTAT; NAVELBINE; PANOBINOSTAT; RITUXIMAB; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT;

ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CONTINUOUS INFUSION; DEATH; DRUG MEGADOSE; DYSPNEA; FATIGUE; HODGKIN DISEASE; HUMAN; HYPERLIPIDEMIA; IMMUNOTHERAPY; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BORONIC ACIDS; DRUG THERAPY; HISTONE DEACETYLASE INHIBITORS; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; PROTEASE INHIBITORS; PYRAZINES; RECURRENCE; SIROLIMUS; THALIDOMIDE;

EID: 84859395758     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0258     Document Type: Review

References (95)

1. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005;23:6400-6408.
2. Duggan DB, Petroni GR, Johnson JL et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 2003;21:607-614.
3. Johnson PW, Radford JA, Cullen MH et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005;23:9208-9218.
4. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339:1506-1514.
5. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009;497-506.
6. Oza AM, Ganesan TS, Leahy M et al. Patterns of survival in patients with Hodgkin's disease: Long follow up in a single centre. Ann Oncol 1993;4:385-392.
7. Quddus F, Armitage JO. Salvage therapy for Hodgkin's lymphoma. Cancer J 2009;15:161-163.
8. Marafioti T, Hummel M, Foss HD et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000;95:1443-1450.
9. Federico M, Luminari S, Iannitto E et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodg-kin's lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805-811.
10. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002;359:2065-2071.
11. Martin A, Fernàndez-Jiménez MC, Caballero MD et al. Long-term follow-up in patients treated with mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001; 113:161-171.
12. Younes A, Bartlett NL, Leonard JP et al. Bren-tuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821.
13. Salit RB, Bishop MR, Pavletic SZ. Allogeneic hematopoietic stem cell transplantation: Does it have a place in treating Hodgkin lymphoma? Curr Hematol Malig Rep 2010;5:229-238.
14. Varterasian M, Ratanatharathorn V, Uberti JP et al. Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation. Leuk Lymphoma 1995;20:59-65.
15. Peggs KS, Anderlini P, Sureda A. Allogeneic transplantation for Hodgkin lymphoma. Br J Haematol 2008;143:468-480.
16. Alvarez I, Sureda A, Caballero MD et al. Non-myeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12:172-183.
17. Corradini P, Sarina B, Farina L. Allogeneic transplantation for Hodgkin's lymphoma. Br J Haematol 2011;152:261-272.
18. Sarina B, Castagna L, Farina L et al. Allogeneic transplantation improves the overall and progres-sion-free survival of Hodgkin lymphoma patients re-lapsing after autologous transplantation: A retrospective study based on the time of HLA typing and donor availability. Blood 2010;115:3671-3677.
19. Sureda A, Robinson S, Canals C et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:455-462.
20. Bierman PJ, Anderson JR, Freeman MB et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann On-col 1996;7:151-156.
21. Foyil KV, Bartlett NL. Anti-CD30 antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep 2010;5:140-147.
22. Bartlett NL, Younes A, Carabasi MH et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30 he-matologic malignancies. Blood 2008;111:1848-1854.
23. Forero-Torres A, Leonard JP, Younes A et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-179.
24. Ansell SM, Horwitz SM, Engert A et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-2769.
25. Younes A, Forero-Torres A, Bartlett NL et al. Multiple complete responses in a phase 1 dose-esca-lation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood 2008;112 Abstract 1006.
26. Chen R, Gopal AK, Smith SE et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010;116 Abstract 283.
27. ClinicalTrials.gov. A Phase 3 Study of Bren-tuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial). Available at http://www.clinicaltrials.gov/ct2/show/NCT01100502, accessed October, 2011.
28. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 2001;97: 616-623.
29. Engert A, Diehl V, Franklin J et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-4554.
30. Santoro A, Magagnoli M, Spina M et al. Ifosf-amide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007;92:35-41.
31. ClinicalTrials.gov. A Phase 1 Study of Bren-tuximab Vedotin Combined With Multi-Agent Che-motherapy for Hodgkin Lymphoma. Available at http://www.clinicaltrials.gov/ct2/show/NCT01060904, accessed October, 2011.
32. ClinicalTrials.gov. Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35). Available at http://www.clinicaltrials.gov/ct2/show/NCT010 26415, accessed October, 2011.
33. ClinicalTrials.gov. An SGN-35 Trial for Patients who Have Previously Participated in an SGN-35 Study. Available at http://www.clinicaltrials.gov/ct2/show/NCT00947856, accessed October, 2011.
34. Younes A, Romaguera J, Hagemeister F et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310-314.
35. Jones RJ, Gocke CD, Kasamon YL et al. Cir-culating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009;113:5920-5926.
36. Younes A, Fayad LY, Goy A et al. Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin lymphoma: Improvement of event free survival (EFS) in all International Prognostic Score (IPS) groups [abstract 2742]. Blood 2006;108:2742.
37. Wedgwood AR, Fanale MA, Fayad LE et al. Rituximab ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy [a]. Blood 2007;110:215.
38. Copeland AR, Cao Y, Fanale M et al. Final report of a phase-II study of rituximab plus ABVD for patients with newly diagnosed advanced stage clas-sical Hodgkin lymphoma: Results of long follow up and comparison to institutional historical data. Blood 2009;114 Abstract 1680.
39. ClinicalTrials.gov. R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma. Available at http://www.clinicaltrials.gov/ct2/show/NCT00992030, accessed October, 2011.
40. ClinicalTrials.gov. HD18 for Advanced Stages in Hodgkins Lymphoma. Available at http://www. clinicaltrials.gov/ct2/show/NCT00515554, accessed October, 2011.
41. ClinicalTrials.gov. Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease. Available at http://www.clinicaltrials.gov/ct2/show/NCT00797472, accessed October, 2011.
42. ClinicalTrials.gov. Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin's Lymphoma. Available at http://www.clinicaltrials.gov/ct2/show/NCT00369681, accessed October, 2011.
43. ClinicalTrials.gov. Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma. Available at http://www.clinicaltrials.gov/ct2/show/NCT00654732, accessed October, 2011.
44. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-784.
45. Cotto M, Cabanillas F, Tirado M et al. Epige-netic therapy of lymphoma using histone deacetylase inhibitors. Clin Transl Oncol 2010;12:401-409.
46. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27: 5459-5468.
47. Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009: 507-519.
48. Ushmorov A, Leithauser F, Sakk O et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006;107:2493-2500.
49. Georgakis GV, Yazbeck VY, Li Y et al. The histone deacetylase inhibitor vorinostat (SAHA) induces apoptosis and cell cycle arrest in Hodgkin lymphoma (HL) cell lines by altering several survival signaling pathways and synergizes with doxorubicin, gemcitabine and bortezomib. Blood 2006; 108 Abstract 2260.
50. Kirschbaum MH, Goldman BH, Zain JM et al. Vorinostat (suberoylanilide hydroxamic acid) in re-lapsed or refractory Hodgkin lymphoma: SWOG 0517. Blood 2007;110 Abstract 2574.
51. Smith JL, Patel A, Fan S et al. Histone deacetylase inhibition using LBH589 is effective in lymphoma and results in down-regulation of the NF-KB pathway. Blood 2009;114 Abstract 3730.
52. Ottmann OG, Spencer A, Prince HM et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrat-ing efficacy in patients with advanced hematologic malignancies. Blood 2008;112 Abstract 958.
53. Sureda A, Younes A, Ben-Yehuda D et al. Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant. Blood 2010;116 Abstract 419.
54. Sureda A, Engert A, Browett PJ et al. Interim results for the phase II study of panobinostat (LBH589) in patients (pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT). J Clin Oncol 2010;28(15 suppl):Abstract 8007.
55. ClinicalTrials.gov. A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma. Available at http://www.clinicaltrials.gov/ct2/show/NCT01034163, accessed October, 2011.
56. ClinicalTrials.gov. Panobinostat Plus Ifosf-amide, Carboplatin, and Etoposide (ICE) Compared With ICE for Relapsed Hodgkin Lymphoma. Avail-able at http://www.clinicaltrials.gov/ct2/show/NCT01169636, accessed October, 2011.
57. Younes A, Hernandez F, Bociek RG et al. ENGAGE-501: Phase 2 study investigating the role of epigenetic therapy with entinostat (SNDX-275) in relapsed and refractory Hodgkin's lymphoma (HL), interim results. Blood 2010;116 Abstract 3959.
58. Younes A, Bociek RG, Kuruvilla J et al. Mocetinostat (MGCD0103), an isotype-selective his-tone deacetylase (HDAC) inhibitor, produces clinical responses in relapsed/refractory Hodgkin lymphoma (HL): Update from a phase II clinical study. Blood 2010;116 Abstract 1763.
59. Blum KA. Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program 2010; 2010;93-100.
60. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
61. Younes A, Copeland A, Fanale MA et al. Phase I/II study of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/ refractory Hodgkin and non-Hodgkin lymphoma. Blood 2010;116 Abstract 3964.
62. Hernandez-Ilizaliturri FJ, Mavis C, Maraj I et al. Panobinostat, a novel histone deacetylase (HiDAC) inhibitor enhances the antitumor activity of bortezomib (BTZ) in rituximab-chemotherapy sensitive and resistant lymphoma cell lines. Blood 2010;116 Abstract 3936.
63. Lemoine M, Buglio D, Jona A et al. The pan-deacetylase inhibitor panobinostat downregulates HIF-1 and VEGF and, synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 2010;116: Abstract 2851.
64. Bartlett JB, Michael A, Clarke IA et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004;90:955-961.
65. Böll B, Borchmann P, Topp MS et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 2010;148:480-482.
66. Fehniger TA, Larson S, Trinkaus K et al. A phase II multicenter study of lenalidomide in re-lapsed or refractory classical Hodgkin lymphoma. Blood 2009;114 Abstract 3693.
67. Kuruvilla J, Taylor D, Wang L et al. Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. Blood 2008;112 Abstract 3052.
68. Böll B, Fuchs M, Reiners KS et al. Lenalido-mide in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010;116:Abstract 2828.
69. Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features com-pared with other alkylating agents. Clin Cancer Res 2008;14:309-317.
70. Moskowitz AJ, Hamlin PA Jr, Gerecitano J et al. Bendamustine is highly active in heavily pretreated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant. Blood 2009;114 Abstract 720.
71. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer ther-apy. J Clin Oncol 2009;27:2278-2287.
72. Schmitz R, Stanelle J, Hansmann ML et al. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 2009;4: 151-174.
73. Vignot S, Faivre S, Aguirre D et al. MTOR-targeted therapy of cancer with rapamycin deriva-tives. Ann Oncol 2005;16:525-537.
74. Yee KW, Zeng Z, Konopleva M et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006;12:5165-5173.
75. Johnston PB, Inwards DJ, Colgan JP et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320-324.
76. ClinicalTrials.gov. Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-Dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine-or Vinorelbine-or Vinblastine-Based Treatment. Available at http://www.clinicaltrials.gov/ct2/show/NCT01022996, accessed October, 2011.
77. von Tresckow B, Borchmann P, Fuchs M et al. Current strategies in refractory or relapsed Hodgkin lymphoma. Haematologica 2010;95:Abstract S31.
78. ClinicalTrials.gov. Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma. Available at http://www.clinicaltrials.gov/ct2/show/NCT00962507, accessed October, 2011.
79. ClinicalTrials.gov. Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma. Available at http://www.clinicaltrials.gov/ct2/show/NCT01075321, accessed October, 2011.
80. Sweetenham J. Analyzing the use of CHOP-rituximab vs. dose-adjusted EPOCH-rituximab in the treatment of clinical stage IVB diffuse large B-cell lymphoma (DLBCL). ASH 2011;Abstract 2717.
81. Fiebrich HB, Siemerink EJ, Brouwers AH et al. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. The Oncologist 2011;16: 783-787.
82. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009;360:195-197.
83. Ghosh S, May MJ, Kopp EB. NF-B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260.
84. Georgakis GV, Li Y, Humphreys R et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin-and bortezomib induced cell death. Br J Haematol 2005;130:501-510.
85. Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 2006; 107:1731-1732.
86. Blum KA, Johnson JL, Niedzwiecki D et al. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and Leu-kemia Group B protocol 50206. Leuk Lymphoma 2007;48:1313-1319.
87. Fanale MA, Fayad L, Pro B et al. Safety and efficacy of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory classical Hodgkin's lymphoma. Blood 2007;110 Abstract 4506.
88. Fanale MA, Fayad LE, Pro B et al. A phase I study of bortezomib in combination with ICE (BICE) in patients with relapsed/refractory classical Hodgkin lymphoma. Blood 2008;112:Abstract 3048.
89. Fanale M, Fayad L, Kwak LW et al. A randomized phase II study of bortezomib plus ICE (BICE) versus ICE for patients with relapsed or refractory Hodgkin lymphoma. Haematologica 2010;95:Abstract S29.
90. Bartlett NL, Niedzwiecki D, Johnson JL et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071-1079.
91. Baetz T, Belch A, Couban S et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003;14:1762-1767.
92. Stokoe CT, Ogden J, Jain VK. Activity of infu-sional etoposide, vincristine, and doxorubicin with bolus cyclophosphamide (EPOCH) in relapsed Hodgkin's disease. The Oncologist 2001;6:428-434.
93. Aparicio J, Segura A, Garcerà S et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999;10:593-595.
94. Josting A, Rudolph C, Reiser M et al. Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002;13:1628-1635.
95. Ferme C, Bastion Y, Lepage E et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995;6:543-549.